The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.
 
Martin F. Kaiser
Honoraria - Amgen; Celgene; Janssen Oncology; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Chugai Pharma; GlaxoSmithKline; Janssen Oncology; Seagen; Takeda
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Janssen; Takeda
 
Andrew Hall
No Relationships to Disclose
 
Katrina Walker
No Relationships to Disclose
 
Ruth De Tute
No Relationships to Disclose
 
Sadie Roberts
No Relationships to Disclose
 
Emma Ingleson
No Relationships to Disclose
 
Kristian Bowles
Research Funding - Abbvie (Inst); Janssen (Inst)
 
Mamta Garg
Travel, Accommodations, Expenses - Takeda
 
Anand Lokare
No Relationships to Disclose
 
Christina Messiou
No Relationships to Disclose
 
Graham H. Jackson
Honoraria - Amgen; Celgene/Bristol-Myers Squibb; Janssen; MSD; Roche; Takeda
Consulting or Advisory Role - Amgen; Celgene/Bristol-Myers Squibb; Janssen; MSD; Roche; Takeda
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Celgene; Takeda
 
Guy Pratt
Honoraria - Amgen; BEIGENE; Binding Site; Celgene; Gilead Sciences; Janssen Oncology; Sanofi/Aventis; Takeda
 
Gordon Cook
Honoraria - Amgen; Celgene/Bristol-Myers Squibb; Janssen; Roche; Sanofi; Takeda
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Janssen (Inst); Takeda (Inst)
 
Mark Drayson
Stock and Other Ownership Interests - Abingdon Health
 
Roger G. Owen
Honoraria - AstraZeneca; BeiGene; Celgene; Janssen-Cilag
Consulting or Advisory Role - BeiGene; Janssen-Cilag
 
Sarah R Brown
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Janssen (Inst)
 
Matthew Jenner
Honoraria - Amgen; Celgene/Bristol-Myers Squibb; Janssen; Novartis; Takeda
Consulting or Advisory Role - Amgen; Celgene/Bristol-Myers Squibb; Janssen; Novartis; Takeda
Research Funding - Janssen (Inst)
Travel, Accommodations, Expenses - Amgen; Takeda